Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas

Inclusion Criteria

Inclusion Criteria

Patients must have the following:

- Positive HIV antibody, positive HIV culture or antigen capture, or prior diagnosis of
AIDS by the CDC criteria.

- Diagnosis by pathological examination of large cell or immunoblastic lymphoma within
measurable or evaluable disease.

- Pneumocystis carinii pneumonia (PCP) prophylaxis during the course of the study.

- Signed written informed consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

- Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia
(PCP) diagnosed within 3 weeks.

- Stage IE Central Nervous System lymphomas.

Patients with the following are excluded:

- More than one previous treatment for lymphoma.

- Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia
(PCP) diagnosed within 3 weeks.

- Conditions that preclude obtaining an informed consent.

- Not accessible for scheduled treatment visits or follow-up.

- Stage IE Central Nervous System (CNS) lymphomas.

Prior Medication:

Excluded within 2 weeks of study entry:

- Zidovudine.

- Excluded:

- Doxorubicin dosing = or > 300 mg/m2.

Prior Treatment:

Excluded:

- Received more than one previous treatment regimen for lymphoma.

Required:

- Prophylactic treatment for Pneumocystis carinii pneumonia (PCP) prophylaxis.